Merck & Co., Inc.

MRK Details

Merck & Co., Inc. (NYSE: MRK) is a global healthcare company, which is involved in offering health solutions through its prescription medicines, biologic therapies, vaccines, and animal health products. The company operates via two segments, 1) Pharmaceutical, which offers human health pharmaceutical products for oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular, diabetes, women's health, and vaccine products; and 2) Animal Health, focused on discovery, development, manufacturing, and marketing of veterinary pharmaceuticals, vaccines, and health management services.

Receipt of FDA Approvals: On August 13, 2021, MRK announced the receipt of the US Food and Drug Administration (FDA) approval for its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, WELIREG, for the treatment of von Hippel-Lindau (VHL) disease in adults requiring therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET).

Previously, on August 11, 2021, the FDA also approved the combination of KEYTRUDA, MRK's anti-PD-1 therapy, plus LENVIMA, an Eisai discovered orally available multiple receptor tyrosine kinase inhibitor, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

Q2FY21 Results: The company reported a sharp uptick of 22% in revenues to USD 11.40 billion in Q2FY21 (ended June 30, 2021) compared to USD 9.35 billion in Q2FY20, driven by the continued recovery from the COVID-19 pandemic and strong demand for KEYTRUDA, GARDASIL/GARDASIL 9 (preventive vaccines for cancer and certain human papillomavirus (HPV)), and the animal health products. Net income for Q2FY21 was USD 1.55 billion, lower than USD 3.00 billion in Q2FY20, owing to greater R&D expenses. MRK exited the quarter with a cash balance of USD 8.58 billion and a total debt of USD 26.52 billion.

Key Risks: MRK relies on the sales of its essential products (KEYTRUDA, GARDASIL/GARDASIL 9, JANUVIA/JANUMET, and BRIDION). Any decline in the sales or pricing of these products could adversely impact the company's results of operations and cash flows. Further, the health care industry is subject to strict regulatory, political, and legal scrutiny. The prior approvals of its products may be suspended/withdrawn if they fail to comply with the regulatory requirements.

Outlook: As of Q2FY21, MRK expects its revenue to range from USD 46.4 billion to USD 47.4 billion in FY21, representing a growth of 12% to 14%. FY21 GAAP EPS is estimated to be between USD 4.24 and USD 4.34 (estimated ~2.53 billion shares outstanding on a diluted basis).

Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation

(Analysis by Kalkine Group)

• % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

MRK Daily Technical Chart (Source: REFINITIV)

Stock Recommendation: MRK's stock price surged 4.41% in the past three months and is currently close to the higher-band of the 52-week range of USD 68.38 to USD 83.72. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is 62.43. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 87.50. Considering the correction in the stock price, decent financial performance, strong product pipeline, and current valuation, we recommend a "Hold" rating on the stock at the current price of USD 78.82, up 0.46% as of August 20, 2021, 1:34 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and industry information have been taken from REFINITIV.  

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.